Bofa Reiterates Johnson & Johnson Stock - Mar 18

The Story

BofA has reiterated its rating on Johnson & Johnson following the approval of a psoriasis drug, according to the report. The update centers on $JNJ and the newly approved therapy as a near-term catalyst.

Why It Matters For Your Portfolio

• Analyst confirmation: BofA reiterated its rating for $JNJ, one analyst firm action that signals continued confidence from a major bank.
• Regulatory catalyst: The approval of a psoriasis drug is the trigger for the note, one newly approved therapy that could influence dermatology revenue streams.
• Data limitations: The article does not provide a price target or revenue figures, so the immediate share-price impact for $JNJ is unspecified.

The Trade

Who should care: Growth and specialty-drug focused investors, plus event-driven traders, should note the analyst reaffirmation and the regulatory milestone. What to watch next: monitor company commentary, launch and sales updates for the psoriasis drug, and any follow-up analyst notes for changes to price targets or guidance.